NOTV vs. BIAF, EQ, PRE, RPHM, CKPT, NSPR, ENZ, ZEPP, ALGS, and EUDA
Should you be buying Inotiv stock or one of its competitors? The main competitors of Inotiv include bioAffinity Technologies (BIAF), Equillium (EQ), Prenetics Global (PRE), Reneo Pharmaceuticals (RPHM), Checkpoint Therapeutics (CKPT), InspireMD (NSPR), Enzo Biochem (ENZ), Zepp Health (ZEPP), Aligos Therapeutics (ALGS), and EUDA Health (EUDA). These companies are all part of the "medical" sector.
bioAffinity Technologies (NASDAQ:BIAF) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Inotiv has a consensus price target of $6.19, indicating a potential upside of 189.14%. Given bioAffinity Technologies' higher possible upside, analysts clearly believe Inotiv is more favorable than bioAffinity Technologies.
1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 18.2% of Inotiv shares are owned by institutional investors. 36.4% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 5.8% of Inotiv shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Inotiv has a net margin of -5.67% compared to Inotiv's net margin of -313.34%. bioAffinity Technologies' return on equity of -10.99% beat Inotiv's return on equity.
Inotiv received 18 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.
In the previous week, Inotiv had 10 more articles in the media than bioAffinity Technologies. MarketBeat recorded 15 mentions for Inotiv and 5 mentions for bioAffinity Technologies. Inotiv's average media sentiment score of 0.30 beat bioAffinity Technologies' score of -0.13 indicating that bioAffinity Technologies is being referred to more favorably in the media.
bioAffinity Technologies has higher earnings, but lower revenue than Inotiv. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Inotiv, indicating that it is currently the more affordable of the two stocks.
bioAffinity Technologies has a beta of 3.15, indicating that its share price is 215% more volatile than the S&P 500. Comparatively, Inotiv has a beta of 3.37, indicating that its share price is 237% more volatile than the S&P 500.
Summary
Inotiv beats bioAffinity Technologies on 11 of the 16 factors compared between the two stocks.
Get Inotiv News Delivered to You Automatically
Sign up to receive the latest news and ratings for NOTV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NOTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
